Steatosis is a comorbid factor for cancer development.
Patients with steatosis do not respond well to current immune checkpoint therapy (CPI) treatment.
We explored the roles of neutrophil-activating chemokines (NACs) in the response of steatosis/liver cancer to CPI.
